Spike SARS CoV-2 OMICRON mRNA has been designed to produce high expression level of OMICRON mutant spike protein of SARS-CoV-2 virus. Ready-to-use stabilised Spike SARS CoV-2 OMICRON mutant (A67V; H69-; V70-; T95I; G142-; V143-; Y144-; Y145D; N211-; L212I; ins EPE 214; G339D; S371L; S373P; S375F; K417N; N440K; G446S; S477N; T478K; E484A; Q493R; G496S; Q498R; N501Y; Y505H; T547K;D614G; H655Y; N679K; P681H; N764K; D796Y; N856K; Q954H; N969K; L981F) mRNA. OZ Biosciences mRNAs are produced by in vitro transcription. mRNAs are stabilised at the 5' end by modified nucleotides capping (Cap1) and contain a poly(A) tail at the 3' end. Sequences have been optimised to yield improved stability and performance.

• MRNA38 does not bear any additional nucleotide modifications
• MRNA39 is modified with 5-methoxyuridine (5moU) to reduce innate immune response
• MRNA44 is modified with N1-methyl-pseudouridine (N1-mψ) to reduce innate immune response